NCT02271217 (MILESTONE℠) is a Phase 3 clinical trial of dalfampridine-ER 7.5mg in Post-Ischemic Stroke, sponsored by Acorda Therapeutics.

Who is sponsoring NCT02271217?

NCT02271217 is sponsored by Acorda Therapeutics.

What drugs are being tested in NCT02271217?

Interventions in NCT02271217: Placebo, dalfampridine-ER 7.5mg, dalfampridine-ER 10mg.

What condition does NCT02271217 study?

NCT02271217 studies Post-Ischemic Stroke.

Is NCT02271217 still recruiting?

NCT02271217 is currently completed. Last updated 4 June 2018.

Are results published for NCT02271217?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2018-06-04 · How we verify

NCT02271217: MILESTONE℠

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

This is a Multi-center, Double-blind, Three Arm, Parallel Group, Placebo-controlled, Randomized Study Designed to Evaluate the Efficacy, Safety and Tolerability of Dalfampridine.

Completed Phase 3 Results posted Last updated 4 June 2018

What this trial tests

Phase 3 trial testing Placebo in Post-Ischemic Stroke in 377 participants. Completed in 1 October 2016.

Timeline

1 December 2014

Primary endpoint
1 September 2016

1 October 2016

Quick facts

Lead sponsor	Acorda Therapeutics
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	377
Start date	1 December 2014
Primary completion	1 September 2016
Estimated completion	1 October 2016
Sites	74 locations across United States, Canada

Drugs / interventions tested

Placebo
dalfampridine-ER 7.5mg — full drug profile →
dalfampridine-ER 10mg — full drug profile →

Conditions studied

Post-Ischemic Stroke — all drugs for Post-Ischemic Stroke →

Sponsor

Acorda Therapeutics — full company profile →

Who can join

18 and older, any sex, with Post-Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Proportion of Subjects Who Show at Least a 20% Improvement on the Two Minute Walk Test (2MinWT) at Week 12
Time frame: Week 12
"The 2MinWT measures the distance a subject can walk in 2 minutes. Participants showing at Least a 20% Improvement on the 2MinWT at 12-weeks are considered "Responders".

Sponsor's own description

The objective of this study is to determine the effect of two dose strengths of dalfampridine-Extended Release (ER) tablets, taken twice daily for 12 weeks, on stable walking deficits in subjects with post-ischemic stroke.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A double-blind, randomized, controlled study of two dose strengths of dalfampridine extended release on walking deficits in ischemic stroke.
Page SJ, Kasner SE, Bockbrader M, Goldstein M, et al · · 2020 · cited 1× · PMID 32651338 · DOI 10.3233/rnn-201009

Verify or expand the search:

Other Acorda Therapeutics trials

Trials by the same sponsor.

NCT03887884 — Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder) · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02271217 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Acorda Therapeutics
Last refreshed: 4 June 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02271217.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing